Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction
Autore:
Vaisman, D; Ferguson, JJ;
Indirizzi:
Univ Texas, Hlth Sci Ctr, Baylor Coll Med, St Lukes Episcopal Hosp,Texas Heart Inst, Houston, TX 77030 USA Univ Texas Houston TX USA 77030 p,Texas Heart Inst, Houston, TX 77030 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1965 - 1976
SICI:
1354-3784(200111)10:11<1965:TPOGIR>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLATELET GLYCOPROTEIN IIB/IIIA; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE CORONARY SYNDROMES; BLOCKADE; TRIAL; ANGIOPLASTY; ABCIXIMAB; ANTIBODY; FLOW; MECHANISMS;
Keywords:
antiplatelet therapy; acute myocardial infarction; fibrinolytic therapy; thrombosis;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Ferguson, JJ Univ Texas, Hlth Sci Ctr, Baylor Coll Med, St Lukes EpiscopalHosp,Texas Heart Inst, Mail Code 1-191,POB 20269, Houston, TX 77030 USA Univ Texas Mail Code 1-191,POB 20269 Houston TX USA 77030 USA
Citazione:
D. Vaisman e J.J. Ferguson, "Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction", EXPERT OP I, 10(11), 2001, pp. 1965-1976

Abstract

The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potential to considerably enhance the treatment of AMI patients. A number of recent studies have highlighted the potential incremental benefits with adjunctive IIb/IIIa-targeted therapy. In this review, we will discuss the pathophysiology of myocardial infarction (MI), the physiology androle of platelets in thrombosis and describe the currently available drugs. We will briefly summarise the results of recent clinical trials, discuss some key forthcoming trials and attempt to describe how GP IIb/IIIa antagonists may directly impact the immediate and near future day-to-day care of patients with AMI.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 11:41:52